These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 19275600

  • 1. Polymorphism and crystallization of active pharmaceutical ingredients (APIs).
    Lu J, Rohani S.
    Curr Med Chem; 2009; 16(7):884-905. PubMed ID: 19275600
    [Abstract] [Full Text] [Related]

  • 2. Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques.
    Pindelska E, Sokal A, Kolodziejski W.
    Adv Drug Deliv Rev; 2017 Aug 01; 117():111-146. PubMed ID: 28931472
    [Abstract] [Full Text] [Related]

  • 3. Solid State Concerns During Drug Discovery and Development: Thermodynamic and Kinetic Aspects of Crystal Polymorphism and the Special Cases of Concomitant Polymorphs, Co-Crystals and Glasses.
    Otto DP, De Villiers MM.
    Curr Drug Discov Technol; 2017 Aug 01; 14(2):72-105. PubMed ID: 27908255
    [Abstract] [Full Text] [Related]

  • 4. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals.
    Healy AM, Worku ZA, Kumar D, Madi AM.
    Adv Drug Deliv Rev; 2017 Aug 01; 117():25-46. PubMed ID: 28342786
    [Abstract] [Full Text] [Related]

  • 5. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges.
    Cerreia Vioglio P, Chierotti MR, Gobetto R.
    Adv Drug Deliv Rev; 2017 Aug 01; 117():86-110. PubMed ID: 28687273
    [Abstract] [Full Text] [Related]

  • 6. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.
    Ticehurst MD, Marziano I.
    J Pharm Pharmacol; 2015 Jun 01; 67(6):782-802. PubMed ID: 25677227
    [Abstract] [Full Text] [Related]

  • 7. Benefits and Limitations of Polymorphic and Amorphous Forms of Active Pharmaceutical Ingredients.
    Talaczynska A, Dzitko J, Cielecka-Piontek J.
    Curr Pharm Des; 2016 Jun 01; 22(32):4975-4980. PubMed ID: 27494530
    [Abstract] [Full Text] [Related]

  • 8. Characterization and Quality Control of Pharmaceutical Cocrystals.
    Izutsu KI, Koide T, Takata N, Ikeda Y, Ono M, Inoue M, Fukami T, Yonemochi E.
    Chem Pharm Bull (Tokyo); 2016 Oct 01; 64(10):1421-1430. PubMed ID: 27319284
    [Abstract] [Full Text] [Related]

  • 9. Manipulation of Pharmaceutical Polymorphic Transformation Process Using Excipients.
    Tian B, Ding Z, Zong S, Yang J, Wang N, Wang T, Huang X, Hao H.
    Curr Pharm Des; 2020 Oct 01; 26(21):2553-2563. PubMed ID: 32053064
    [Abstract] [Full Text] [Related]

  • 10. An Examination of Water Vapor Sorption by Multicomponent Crystalline and Amorphous Solids and Its Effects on Their Solid-State Properties.
    Newman A, Zografi G.
    J Pharm Sci; 2019 Mar 01; 108(3):1061-1080. PubMed ID: 30391302
    [Abstract] [Full Text] [Related]

  • 11. New forms of old drugs: improving without changing.
    Domingos S, André V, Quaresma S, Martins IC, Minas da Piedade MF, Duarte MT.
    J Pharm Pharmacol; 2015 Jun 01; 67(6):830-46. PubMed ID: 25648101
    [Abstract] [Full Text] [Related]

  • 12. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, Cima MJ, Gardner CR.
    Adv Drug Deliv Rev; 2004 Feb 23; 56(3):275-300. PubMed ID: 14962582
    [Abstract] [Full Text] [Related]

  • 13. Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies.
    Schenck L, Erdemir D, Saunders Gorka L, Merritt JM, Marziano I, Ho R, Lee M, Bullard J, Boukerche M, Ferguson S, Florence AJ, Khan SA, Sun CC.
    Mol Pharm; 2020 Jul 06; 17(7):2232-2244. PubMed ID: 32392068
    [Abstract] [Full Text] [Related]

  • 14. Investigation of Polymorphism and Cocrystallization of Active Pharmaceutical Ingredients Using Vibrational Spectroscopic Techniques.
    Du Y, Xue J.
    Curr Pharm Des; 2016 Jul 06; 22(32):4917-4928. PubMed ID: 27464725
    [Abstract] [Full Text] [Related]

  • 15. Characterization of pharmaceutically relevant materials at the solid state employing chemometrics methods.
    Calvo NL, Maggio RM, Kaufman TS.
    J Pharm Biomed Anal; 2018 Jan 05; 147():538-564. PubMed ID: 28666554
    [Abstract] [Full Text] [Related]

  • 16. [Polymorph transformation of solid drugs].
    Zhang Q, Mei XF.
    Yao Xue Xue Bao; 2015 May 05; 50(5):521-7. PubMed ID: 26234130
    [Abstract] [Full Text] [Related]

  • 17. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
    Rodríguez-Spong B, Price CP, Jayasankar A, Matzger AJ, Rodríguez-Hornedo N.
    Adv Drug Deliv Rev; 2004 Feb 23; 56(3):241-74. PubMed ID: 14962581
    [Abstract] [Full Text] [Related]

  • 18. State of the Art of Pharmaceutical Solid Forms: from Crystal Property Issues to Nanocrystals Formulation.
    Couillaud BM, Espeau P, Mignet N, Corvis Y.
    ChemMedChem; 2019 Jan 08; 14(1):8-23. PubMed ID: 30457705
    [Abstract] [Full Text] [Related]

  • 19. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.
    Newman A, Reutzel-Edens SM, Zografi G.
    J Pharm Sci; 2018 Jan 08; 107(1):5-17. PubMed ID: 28989014
    [Abstract] [Full Text] [Related]

  • 20. [Crystalline modifications and polymorphism changes during drug manufacture].
    Doelker E.
    Ann Pharm Fr; 2002 May 08; 60(3):161-76. PubMed ID: 12050595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.